Abbott has received approval from the U.S. Food and Drug Administration for its fully automated HTLV-I/HTLV-II blood screening test for use on the ABBOTT PRISM instrument.

Abbott a health care company,  the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritional, devices and diagnostics. Abbott Diagnostics is a global leader in vitro diagnostics and offers a broad range of innovative instrument systems and tests for hospitals, reference labs, blood banks, physician offices and clinics.

Abbott has received approval from the U.S. Food and Drug Administration for its fully automated HTLV-I/HTLV-II blood screening test for use on the ABBOTT PRISM instrument. The test is intended for use by laboratories to screen individual donations of blood and plasma for antibodies to human T – lymphotropic virus Type I and/or human T – lymphotropic virus Type II (anti-HLTV-I/HTLV-II).

The PRISM instrument consolidates testing into a single system automating many of the manual testing procedures and steps currently used to screen blood. Safety features built into the system help track and monitor each sample throughout the testing process providing documentation and quality control for testing facilities. The PRISM system can run 160 samples per hour, making it possible to test more than 1,200 samples per eight-hour shift.

HTLV-I and HTLV-II are closely related but distinct retroviruses associated with several diseases including human T-cell leukemia and neurological disorders, according to the Centers for Disease Control. Screening of the U.S. blood supply for HTLV-I/II began in 1988.

Used in more than 30 countries, the PRISM system also includes four hepatitis tests: a core hepatitis B test (PRISM HBcore), introduced in October 2005; two hepatitis B surface antigen tests (PRISM HBsAg and HBsAg Confirmatory), introduced in July 2006; and a hepatitis C test (PRISM HCV), introduced in July 2007.